Moreover, EPHA2 and EPHB1 are overexpressed in neurofibromatosis type 2 gene (NF2) deficient meningiomas, and their pharmaceutical targeting with Dasatinib favors patients’ prognosis [98]. This evidence concerns the gene NF2 and meningioma.